News & Events

CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S. Ullian, the three Director nominees. The terms of the Directors elected at the 2007 Annual Meeting of Stockholders will expire at the 2010 Annual Meeting of Stockholders.

At a Board of Directors meeting held subsequent to the Annual Meeting of Stockholders, the Board of Directors re-elected Charles A. Sanders, M.D. as Chairman of the Board. Dr. Sanders has been a member of Vertex's Board since 1996 and Chairman since 2006. He also serves as the Chairman of the Corporate Governance and Nominating Committee of the Board of Directors. Dr. Sanders has held various leadership positions at major pharmaceutical companies, including Chairman of Glaxo Inc. and Vice Chairman at Squibb Corporation.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

(VRTX-GEN)

SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-444-6108
Director, Corporate Communications
or
Lora Pike, 617-444-6755
Manager, Investor Relations

Copyright Business Wire 2007

News Provided by COMTEX